背景:肿瘤免疫治疗已成为术后重要的辅助治疗方法,放射治疗,和化疗。近年来,肿瘤相关抗原(TAA)在肿瘤免疫治疗中的作用日益突出。肿瘤-睾丸抗原(CTA)是一种在多种肿瘤中受到高度限制并能诱导免疫应答的TAA。
目的:本文旨在评估CTA在卵巢癌进展中的作用,其诊断功效,以及免疫疗法的潜力。
方法:我们分析了出版物,并概述了监管机制的全面概述,免疫原性,临床表现意义,肿瘤发生,CTA在卵巢癌中的应用前景,特别关注基于CTA的免疫治疗的最新进展。
结果:CTA的表达影响其发生,发展,卵巢癌的预后与肿瘤免疫密切相关。
结论:CTA可作为卵巢癌诊断和预后评估的生物标志物,是抗肿瘤免疫治疗的理想靶点。这些发现为CTA改善卵巢癌的诊断和治疗提供了新的见解。的成功,还讨论了当前的挑战和未来的前景,以描绘其巨大的潜力。
BACKGROUND: Tumor immunotherapy has become an important adjuvant therapy after surgery, radiotherapy, and chemotherapy. In recent years, the role of tumor-associated antigen (TAA) in tumor immunotherapy has become increasingly prominent. Cancer-testis antigen (CTA) is a kind of TAA that is highly restricted in a variety of tumors and can induce an immune response.
OBJECTIVE: This review article aimed to evaluate the role of CTA on the progression of ovarian cancer, its diagnostic efficacy, and the potential for immunotherapy.
METHODS: We analyzed publications and outlined a comprehensive of overview the regulatory mechanism, immunogenicity, clinical expression significance, tumorigenesis, and application prospects of CTA in ovarian cancer, with a particular focus on recent progress in CTA-based immunotherapy.
RESULTS: The expression of CTA affects the occurrence, development, and prognosis of ovarian cancer and is closely related to tumor immunity.
CONCLUSIONS: CTA can be used as a biomarker for the diagnosis and prognosis evaluation of ovarian cancer and is an ideal target for antitumor immunotherapy. These findings provide novel insights on CTA in the improvement of diagnosis and treatment for ovarian cancer. The successes, current challenges and future prospects were also discussed to portray its significant potential.